It is well established that lipid peroxidation‐reactive oxygen species (ROS) are among the initiating factors in colon cancer and that pro‐inflammatory cytokines, particularly IL‐6, have been related to tumour progression during chronic inflammatory injury.37 In this context, the observation that PENVE significantly reduced the number of tissue‐infiltrating macrophages (Figure S1) suggests that this drug may have a beneficial effect also by reducing inflammatory cytokines from infiltrating immune cells. Here, IL6 is linked to malignant colon neoplasm.